» Articles » PMID: 36880809

Camurati-Engelmann Disease: A Case-Based Review About an Ultrarare Bone Dysplasia

Overview
Journal Eur J Rheumatol
Publisher Aves
Specialty Rheumatology
Date 2023 Mar 7
PMID 36880809
Authors
Affiliations
Soon will be listed here.
Abstract

Camurati-Engelmann disease or progressive diaphyseal dysplasia is a rare hereditary disease that results in a symmetrical hyperostosis of the long bones (cortical thickening) and/or the base of the skull. Camurati-Engelmann disease is also associated with myopathy and neurological manifestations. Clinically, Camurati-Engelmann disease typically presents with bone pain in the lower extremities, muscle weakness, and a wobbly, stilted gait. The disease is caused by mutations in the transforming growth factor-beta 1 gene. Up to date, about 300 cases have been described in the literature. In this case-based review, we present the clinical picture and genetic and radiological findings in a 20-yearold male patient we diagnosed with Camurati-Engelmann disease and our considerations in his treatment and compare the case to the literature. The diagnosis of Camurati-Engelmann disease was confirmed on patients' history, clinical and radiological findings, and genetic testing for transforming growth factor beta-1 mutation. The patient responded well to single therapy with zoledronic acid. Early diagnosis leads to improved clinical outcomes and increased quality of life in affected patients.

Citing Articles

Sterile osteomyelitis: a cardinal sign of autoinflammation.

Borges T, Santos J, Silva S Reumatologia. 2025; 62(6):475-488.

PMID: 39866303 PMC: 11758105. DOI: 10.5114/reum/196595.


Phenotypic Variability in Camurati-Engelmann Disease: A Case Report of a Family with the c.653G>A Pathogenic Variant in the Gene.

Campos T, Uchoa E, Santos V, Zatarin R, Benicio R, Gomes C Genes (Basel). 2024; 15(11).

PMID: 39596554 PMC: 11593567. DOI: 10.3390/genes15111354.

References
1.
Noain-Sanz E, Martinez de Morentin-Garraza J, Eslava-Gurrea E . [Intramedullary reaming in Ribbing disease]. Rev Esp Cir Ortop Traumatol. 2013; 57(3):231-4. DOI: 10.1016/j.recot.2013.02.004. View

2.
Trombetti A, Cortes F, Kaelin A, Morris M, Rizzoli R . Intranasal calcitonin reducing bone pain in a patient with Camurati-Engelmann disease. Scand J Rheumatol. 2011; 41(1):75-7. DOI: 10.3109/03009742.2011.608195. View

3.
Cooper M, Hewison M, Stewart P . Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol. 1999; 163(2):159-64. DOI: 10.1677/joe.0.1630159. View

4.
Yuldashev A, Shin C, Kim Y, Jang W, Park M, Chae J . Orthopedic Manifestations of Type I Camurati-Engelmann Disease. Clin Orthop Surg. 2017; 9(1):109-115. PMC: 5334020. DOI: 10.4055/cios.2017.9.1.109. View

5.
Herrera S, Soriano R, Nogues X, Guerri-Fernandez R, Grinberg D, Garcia-Giralt N . Discrepancy between bone density and bone material strength index in three siblings with Camurati-Engelmann disease. Osteoporos Int. 2017; 28(12):3489-3493. DOI: 10.1007/s00198-017-4198-6. View